The US Non-Invasive Prenatal Testing (NIPT) Market 2020 Precise Outlook – Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), Illumina, Natera, Quest Diagnostics

The United States Non-Invasive Prenatal Testing (NIPT) Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

United States Non-Invasive Prenatal Testing (NIPT) Market is likely to reach nearly USD 1 Billion by the year end of 2023.

Market growth can be attributed to factors such as rapid penetration of high and average risk NIPT test, high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT, shifting trend towards child bearing at advanced maternal age (35 years or older), launch of new and advanced NIPT products. With increased patient access to NIPT test, United States NIPT test market is anticipated to have a positive outlook in the coming years.

Buy This Report:
https://www.marketinsightsreports.com/report/purchase/04272008262?mode=su?source=openpr&Mode=12

Top Leading Companies of United States Non-Invasive Prenatal Testing (NIPT) Market are Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), Illumina, Natera, Quest Diagnostics and others.

BURLINGTON, N.C.- Aug. 19, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of the informaSeq Prenatal Test.

The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can assess risk for multiple fetal chromosomal aneuploidies, or abnormalities in the number of chromosomes, from a single maternal blood draw. There are testing options for several additional common sex-related aneuploidies. The test is offered through Integrated Genetics, part of the LabCorp Specialty Testing Group of laboratories that offer advanced esoteric and genomic testing.

The American Congress of Obstetricians and Gynecologists (ACOG) and the Society of Maternal Fetal Medicine (SMFM) recognize the tremendous potential of cell-free DNA (cfDNA) testing, concluding that cfDNA testing can be offered to patients at increased risk of aneuploidy. The informaSeq Prenatal Test is performed using Illumina sequencing technology to generate test data, offering high detection rates (sensitivity) and low false positive rates (specificity), even in samples with a lower fraction of fetal DNA fragments.

SAN JOSE, Calif., June 11, 2015 -- Roche (SIX: RO, ROG;OTCQX:RHHBY). Ariosa Diagnostics, Inc., a global leader in non-invasive prenatal testing (NIPT) technology and maker of the Harmony Prenatal Test, today announced that it has granted licenses to laboratories so that they can develop, validate, and conduct NIPT using the same technology that Ariosa has provided to over 500,000 women globally to date.

"Through these license agreements, Ariosa now enables laboratories to locally perform NIPT with the same technology we use in our CLIA laboratory in California to perform the Harmony Prenatal Test," said Ken Song, CEO of Ariosa Diagnostics. "They represent a significant step in reaching our goal to offer the broadest access to the world's leading and most validated NIPT to pregnant women worldwide."

2 December 2014: Roche today announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology.
Ariosa’s proprietary HarmonyTM Prenatal Test is a blood test that is performed as early as 10 weeks into pregnancy. By evaluating fetal cfDNA found in maternal blood, the test is designed to assess the risk of Down syndrome and other genetic abnormalities. Specifically, the test assesses the risk of trisomies 13, 18, and 21, which are indicative of an extra chromosome in the fetus that can lead to severe genetic conditions.

The HarmonyTM Prenatal Test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories.*
This allows understanding of the market and benefits from any lucrative opportunities that are available. Researchers have offered a comprehensive study of the existing market scenario while concentrating on the new business objectives. There is a detailed analysis of the change in customer requirements, customer preferences, and the vendor landscape of the overall market.

Get Sample Report:
https://www.marketinsightsreports.com/reports/04272008262/united-states-non-invasive-prenatal-testing-nipt-market-insights-opportunity-analysis-growth-potential-demand-forecast-2017-2023/inquiry?source=openpr&Mode=12

Following are major Table of Content of United States Non-Invasive Prenatal Testing (NIPT) Industry:

• United States Non-Invasive Prenatal Testing (NIPT) Market Sales Overview.
• United States Non-Invasive Prenatal Testing (NIPT) Market Sales Competition by Manufacturers.
• United States Non-Invasive Prenatal Testing (NIPT) Market Sales Analysis by Region.
• United States Non-Invasive Prenatal Testing (NIPT) Market Sales Analysis by Type.
• United States Non-Invasive Prenatal Testing (NIPT) Market Analysis by Application.
• United States Non-Invasive Prenatal Testing (NIPT) Market -Manufacturers Analysis.

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics - We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and interferences.

Identifying key cannibalizes - Strong substitute of a product or service is the most important threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends – The report help clients to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis help clients to have early mover advantage.

Interrelated opportunities - This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in real world.

We Offer Customization on report based on specific client Requirement:

– Free country Level analysis for any 5 countries of your choice.
– Free Competitive analysis of any 5 key market players.
– Free 40 analyst hours to cover any other data point.

Browse Full Report at:
https://www.marketinsightsreports.com/reports/04272008262/united-states-non-invasive-prenatal-testing-nipt-market-insights-opportunity-analysis-growth-potential-demand-forecast-2017-2023?source=openpr&Mode=12

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.